İlker Taşçı

Gülhane Askeri Tıp Akademisi, İç Hastalıkları Anabilim Dalı, Ankara-*Türkiye*

Yazışma Adresi/Address for Correspondence: Dr. İlker Taşçı Gülhane Askeri Tıp Akademisi, İç Hastalıkları Anabilim Dalı, Etlik, 06018 Ankara-*Türkiye* Tel: +90 312 304 31 19 Faks: +90 312 304 40 00 E-posta: ilkertasci@yahoo.com

Çevrimiçi Yayın Tarihi/Available Online Date: 22.06.2012

© Telif Hakkı 2012 AVES Yayıncılık Ltd. Şti. - Makale metnine www.anakarder.com web sayfasından ulaşılabilir.

©Copyright 2012 by AVES Yayıncılık Ltd. - Available on-line at www.anakarder.com doi:10.5152/akd.2012.167

Mobile right heart thrombus as a manifestation of homozygous mutation of MTHFR 1298 A > C

Homozigot MTHFR 1298 A > C mutasyonunun belirtisi olarak mobil sağ atriyal trombüs vakası

Dear Editor,

Mobile right heart thrombus (MRHT) is uncommon pathology but the true prevalence is still unknown. Previous studies reported that MRHT occurs in 7% to 18% of patients with pulmonary embolism with high mortality rate (44.7%) (1). The main manifestations of venous thromboembolism (VTE) are deep venous thrombosis (DVT) and pulmonary embolism. In addition, genetic factors play an important role in pathogenesis of VTE. The relationship between common genetic mutations such as factor V Leiden, prothrombin factor II G 20210A, methylenetetrahydrofolate reductase (MTHFR), deficiencies of protein C, protein S, and antithrombin III, and VTE have been reported (2).

A 34-year-old man admitted to the emergency department because of sudden onset of dyspnea. He had no previous history of both VTE and acute coronary syndrome. He denied any trauma, history of malignancy, recent surgery, and any drug usage. Only 10 days before, he had fracture of toe, which did not require plaster cast and immobilization. Admission physical examination was unremarkable. Baseline 12-lead electrocardiogram (ECG) revealed sinus rhythm and S1Q3T3 sign. Duplex scan of the lower extremities was also normal. Because of suspicion of pulmonary embolism, bedside transthoracic echocardiography (TTE) was performed, which revealed mobile right atrial mass. Left ventricular ejection fraction was normal (60%). Right ventricle was not enlarged and estimated systolic pulmonary arterial pressure was 28 mmHg. Because of poor imaging quality with TTE, transesophageal echocardiography (TEE) was performed and two hypermobile and snake-like thrombi in the right atrium were demonstrated (Fig. 1 and Video 1. See corresponding video/movie images at www.anakarder. com). Laboratory parameters were within normal limits. Protein C and S levels were also normal. Homocysteine was slightly elevated: 19.6 µmol/L (5.5-14 µmol/L). Upon genetic testing, there were no mutations in the factor V Leiden (G1691A), factor II (G20210A), and MTHFR (C677T). Only homozygous mutation of MTHFR (A1298C) was detected. Pulmonary computed tomography angiography revealed bilateral lower lobe pulmonary embolism (Fig. 2). Because of hemodynamic stability and no evidence of RV strain, anticoagulation with heparin was started. After 10 days of hospitalization, control TEE was performed and right atrial thrombi were markedly decreased (Fig. 3 and Video 2. See corresponding video/movie images at www.anakarder.com). The patient was discharged with warfarin treatment for indefinite time.

The relationship between both C677T and A1298C polymorphisms of the MTHFR gene and VTE have been analyzed before (3). However, there are conflicting results regarding the role of MTHFR gene mutation in VTE pathogenesis (4). In cases of homozygous MTHFR mutations, hyperhomocysteinemia may occur. The relationship between hyperhomocysteinemia and VTE is still unknown and conflicting results are present. Auerbach et al. (5) have reported that homozygous MTHFR mutation that leads to hyperhomocysteinemia can increase the risk of VTE up to 2.5-folds. Therefore, in the present case, we postulated that the possible cause of right atrial thrombi is MTHFR A1298C homozygous mutation because no other predisposing factors were present in our patient. In addition, previous cases of VTE were presented with heterozygous MTHFR mutation. However, our patient had homozygous MTHFR mutation and, right heart thrombus as a manifestation of homozygous



Figure 1. Pretreatment transesophageal echocardiography showing two mobile thrombi in the right atrium





Figure 2. Pulmonary computed tomography showing bilateral thrombi in the lower lobi



Figure 3. Post-anticoagulation therapy, transesophageal echocardiography showing markedly reduced thrombi in the right atrium PA - pulmonary artery, RA - right atrium, RV - right ventricle, Th - thrombus

MTHFR mutation has not been reported before. In conclusion, we suggest analyzing genetic mutations in patients with VTE who had not any predisposing factors. Because diagnosis of genetic mutation associated with VTE will require long-term anticoagulation.

Enes Elvin Gül, Halil İbrahim Erdoğan, Ufuk Tan Bayram, Kurtuluş Özdemir

Department of Cardiology, Meram School of Medicine, Selçuk University, Konya-*Turkey*

Video 1. Pretreatment transesophageal echocardiography showing two mobile thrombi in the right atrium

PA - pulmonary artery, RA - right atrium, RV - right ventricle, Th - thrombus Video 2. Post-anticoagulation therapy, transesophageal echocardiography showing markedly reduced thrombi in the right atrium PA - pulmonary artery, RA - right atrium, RV - right ventricle, Th - thrombus

References

- Casazza F, Bongarzoni A, Centonze F, Morpurgo M. Prevalence and prognostic significance of right-sided cardiac mobile thrombi in acute massive pulmonary embolism. Am J Cardiol 1997; 79: 1433-5. [CrossRef]
- Nizankowska-Mogilnicka E, Adamek L, Grzanka P, Domagala TB, Sanak M, Krzanowski M, et al. Genetic polymorphisms associated with acute pulmonary embolism and deep venous thrombosis. Eur Respir J 2003; 21: 25-30. [CrossRef]
- Isotalo PA, Donnelly JG. Prevalence of methylenetetrahydrofolate reductase mutations in patients with venous thrombosis. Mol Diagn 2000; 5: 59-66.
 [CrossRef]
- Bezemer ID, Doggen CJ, Vos HL, Rosendaal FR. No association between the common MTHFR 677C->T polymorphism and venous thrombosis: results from the MEGA study. Arch Intern Med 2007; 167: 497-501. [CrossRef]
- Auerbach AD, Sanders GD, Hambleton J. Cost-effectiveness of testing for hypercoagulability and effects on treatment strategies in patients with deep vein thrombosis. Am J Med 2004; 116: 816-28. [CrossRef]

Address for Correspondence/Yazışma Adresi: Enes Elvin Gül, MD

Selçuk Üniversitesi, Meram Tıp Fakültesi, Kardiyoloji Sekreterliği, Meram, 42090 Konya-*Türkiye*

Phone: +90 332 223 60 72 Fax: +90 332 323 71 21 E-mail: elvin_salamov@yahoo.com

Available Online Date/Çevrimiçi Yayın Tarihi: 22.06.2012

© Telif Hakkı 2012 AVES Yayıncılık Ltd. Şti. - Makale metnine www.anakarder.com web sayfasından ulaşılabilir.

©Copyright 2012 by AVES Yayıncılık Ltd. - Available on-line at www.anakarder.com doi:10.5152/akd.2012.168

Paroxysmal supraventricular arrhythmias during hypokalemic episodes in a patient with hypokalemic periodic paralysis

Hipokalemik periyodik paralizili bir hastada hipokalemik epizodlar sırasında gelişen paroksismal supraventriküler aritmiler

Dear Editor,

A 21-year-old female patient was admitted to our hospital with severe muscle weakness, fatigue, unable to move all extremities and palpitation following a high carbohydrate meal. The patient described similar symptoms a week ago, which she recovered spontaneously in 48 hours. Her past and family history was unremarkable. Physical examination was notable for flaccid tetraparesis, decreased deep tendon reflexes, with sparing of the facial, oropharyngeal and respiratory muscles. Sensory testing was intact. Thyroid and other system examinations were unremarkable. Electrocardiography (ECG) on admission revealed supraventricular tachycardia (180 bpm) (Fig. 1A). Initial laboratory tests showed a potassium level of 2.67 mEg/L (normal range 3.5-5.1 mEg/L); all the other routine examinations and thyroid hormone levels were normal. She presented sinus rhythm after intravenous potassium replacement and diltiazem (12.5 mg). Control potassium level showed 3.78 mEa/L. Electrophysiological study revealed dual AV nodal physiology, inability to induce any tachycardia and no ablation therapy. She discharged uneventfully. While she was asymptomatic for 2 months, the patient admitted to emergency room with palpitation again. ECG on admission showed atrial tachycardia (166 bpm) (Fig. 1B). In addition, biochemistry tests showed potassium level of 2.78 mEg/L. Her palpitation was resolved after intravenous potassium replacement again. She was referred for investigation of the reasons of hypokalemia. Serum potassium levels were normal in between emergency admissions. Also serum magnesium, sodium, calcium levels and thyroid function tests were in normal limits. Urinary potassium level was decreased (24 mEq/L). Urinary potassium/creatinine ratio was 0.50. Transtubular potassium gradient was 6.8 (normal range: 7-9). Arterial blood gas analysis showed no metabolic alkalosis. Serum renin, aldosterone and ACTH levels were normal. Adrenal gland imaging with computed tomography revealed normal findings. So, hypokalemic periodic paralysis was considered in differential diagnosis, which was confirmed by genetic testing (mutation in SCN4A, Arg669H). The patient was discharged with oral potassium supplement (potassium citrate 2.17 gr/ day plus potassium carbonate 2.0 gr/day) and avoidance of strenuous exercise and high carbohydrate diet. The 6-months follow-up was free of new paralysis and palpitation episodes.

Hypokalemic periodic paralysis is an autosomal dominant disorder which is accompanied by muscle weakness/paralysis and hypokalemia. Attacks can be induced by exercise, carbohydrate-rich meals



Figure 1. Initial electrocardiography showing supraventricular tachycardia (180 bpm) on first admission (A). Atrial tachycardia (166 bpm) was also seen on second admission (B)